Glucagon-Like Peptide Agonist Pipeline: 60+ Companies Driving Innovation in Treatment

Leading pharma companies are shaping the future of GLP agonist therapies, revolutionizing treatment possibilities.

DelveInsight's 'Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2024' report provides comprehensive global coverage of pipeline Glucagon-like Peptide Agonist therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Glucagon Like Peptide Agonist pipeline domain.

For Glucagon-like Peptide Agonist emerging drugs, the Glucagon Like Peptide Agonist pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Glucagon-Like Peptide Agonist Pipeline Report
• DelveInsight's Glucagon-like Peptide Agonist Pipeline analysis depicts a robust space with 60+ active players working to develop 65+ pipeline drugs for Glucagon-Like Peptide Agonist treatment.
• The leading Glucagon Like Peptide Agonist companies include Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics, and others are evaluating their lead assets to improve the Glucagon Like Peptide Agonist treatment landscape.
• Key Glucagon Like Peptide Agonist pipeline therapies in various stages of development include orforglipron, survodutide, danuglipron, retatrutide, HRS9531, MK-6024, XW014, and others.
• In January 2025, Metsera announced positive results from a phase 2a trial assessing the efficacy and safety of MET-097i for treating obesity and overweight in patients without type 2 diabetes (T2D). The biopharmaceutical company indicated plans to initiate phase 3 trials, pending data from additional studies on the therapy.
• In December 2024, the U.S. Food and Drug Administration approved the first generic version of Victoza (liraglutide injection) 18 mg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist, for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, as an adjunct to diet and exercise.

• In July 2024, MHRA approved GLP-1 receptor agonist semaglutide to reduce the risk of serious heart problems in obese or overweight adults, and semaglutide becomes the first weigh58 t loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease.
• In July 2024, Roche announced that its oral GLP-1 receptor agonist showed promising early weight loss results in Phase I.

Request a sample and discover the recent breakthroughs happening in the Glucagon Like Peptide Agonist pipeline landscape @ https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glucagon-Like Peptide Agonist Overview
Glucagon-Like Peptide (GLP) agonists, particularly GLP-1 receptor agonists, are a vital class of medications for managing type 2 diabetes mellitus. These drugs mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake, playing a key role in glucose homeostasis. By stimulating insulin secretion and inhibiting glucagon release, GLP-1 receptor agonists effectively lower blood sugar levels while minimizing the risk of hypoglycemia.

Several GLP-1 receptor agonists are available, including exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide. These medications are primarily administered via subcutaneous injection, with dosing schedules varying from once daily to once weekly. The extended dosing intervals enhance patient adherence, improving long-term treatment outcomes.

Beyond glycemic control, GLP-1 agonists are instrumental in managing obesity due to their appetite-suppressing and weight-loss benefits. They have also demonstrated cardiovascular advantages by reducing major adverse cardiovascular events (MACE). Additionally, these agents may help preserve pancreatic beta cell function, support liver health in conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and offer potential neuroprotective and renoprotective effects. With their convenient dosing and suitability for combination therapies, GLP-1 receptor agonists represent a promising treatment approach across multiple metabolic and neurological disorders, reinforcing their clinical importance.

Find out more about Glucagon Like Peptide Agonist medication @ https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glucagon Like Peptide Agonist Treatment Analysis: Drug Profile
Survodutide: Boehringer Ingelheim
Survodutide is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action that activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. Survodutide was co-invented by Boehringer Ingelheim and Zealand Pharma. Survodutide has received US FDA Fast Track Designation as well as a PRIME designation in the EU for the treatment of NASH. Survodutide is being evaluated in Phase III trials for people living with obesity, Non-alcoholic steatohepatitis, and Type 2 diabetes mellitus.

HRS9531: Fujian Shengdi Pharmaceutical
HRS9531 is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, offering a treatment option for individuals who are overweight or obese, as well as type 2 diabetes. This Phase II study evaluated the efficacy and safety of HRS9531 in obese adults without diabetes. The research found HRS9531 effectively reduced body weight, blood pressure, blood glucose, and triglycerides, with a favorable safety profile. Currently, the drug is inthe Phase III stage of development for the treatment of obesity.

MK-6024: Merck
MK-6024 is an investigational peptide and dual agonist at glucagon-like peptide 1 (GLP-1) and glucagon receptors in clinical development for the treatment of NASH. MK-6024 is being developed under an exclusive licensing agreement between Merck and Hanmi Pharmaceutical for the treatment of patients with NASH. The US FDA has granted the drug Fast Track Designation for the treatment of NASH, a more severe form of NAFLD. A Phase IIa clinical trial was conducted that compared the efficacy and safety of efinopegdutide to the GLP-1 receptor agonist semaglutide in patients with NAFLD. The results of this trial were presented at the 2023 European Association for the Study of the Liver (EASL) Annual Congress. Currently, the drug is in Phase II stage of its development for the treatment of Non-alcoholic steatohepatitis.

Key Glucagon Like Peptide Agonist Therapies and Companies
• Survodutide: Boehringer Ingelheim
• HRS9531: Fujian Shengdi Pharmaceutical
• MK-6024: Merck
• XW014: Sciwind
• Orforglipron: Eli Lilly and company,
• Survodutide: Boehringer Ingelheim
• Danuglipron: Pfizer
• Retatrutide by Eli Lilly and company
Learn more about the novel and emerging Glucagon Like Peptide Agonist pipeline therapies @ https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glucagon Like Peptide Agonist Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Glucagon Like Peptide Agonist Pipeline Report
• Coverage: Global
• Key Glucagon Like Peptide Agonist Companies: Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics, and others.
• Key Glucagon Like Peptide Agonist Pipeline Therapies: Orforglipron, survodutide, danuglipron, retatrutide, HRS9531, MK-6024, XW014, and others.

Dive deep into rich insights for drugs used for Glucagon Like Peptide Agonist treatment; visit @ https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Glucagon Like Peptide Agonist Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Glucagon Like Peptide Agonist Pipeline Therapeutics
6. Glucagon Like Peptide Agonist Pipeline: Late-Stage Products (Phase III)
7. Glucagon Like Peptide Agonist Pipeline: Late-Stage Products (Phase III)
8. Glucagon Like Peptide Agonist Pipeline: Mid-Stage Products (Phase II)
9. Glucagon Like Peptide Agonist Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Through our subscription-based platform, PharmDelve, you can get hassle-free access to all the healthcare and pharmaceutical market research reports.

This release was published on openPR.